Cagrilintide: The Amylin Analog Paired With Semaglutide for Next-Level Weight Loss

What Is Cagrilintide and How Does It Work?

Cagrilintide is a fatty-acid-acylated, long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin slows gastric emptying, suppresses glucagon, and signals satiety through the area postrema and nucleus tractus solitarius in the brainstem. Native amylin has a half-life of roughly 15 minutes, which is why pramlintide (Symlin), the only approved amylin analog, requires two to three injections daily. Cagrilintide's acylation extends its half-life to approximately seven days, enabling once-weekly dosing that matches semaglutide's schedule and makes a fixed-dose co-formulation practical.

The biological rationale for pairing an amylin analog with a GLP-1 receptor agonist is mechanistic complementarity. Semaglutide acts primarily through GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and slowing gastric emptying via one pathway. Cagrilintide acts through amylin receptors (complexes of calcitonin receptor plus receptor-activity-modifying proteins) in an overlapping but distinct network. Preclinical data in diet-induced obese rodents showed that the combination produced additive and in some conditions synergistic reductions in food intake compared with either agent alone, a finding published in the British Journal of Pharmacology and cited in the phase 2 design rationale [1].

This dual-mechanism approach mirrors the logic behind tirzepatide's GLP-1 plus GIP dual agonism, but it targets a different second pathway. Where tirzepatide amplifies incretin signaling, CagriSema adds a centrally-acting satiety signal that operates independently of incretin receptors, which may explain why weight loss plateaus occur at different thresholds with each combination.

Phase 2 Trial Data: What We Knew Before REDEFINE

The key phase 2 dose-finding study (N=96 adults with overweight or obesity, BMI 27 to 50 kg/m²) randomized participants to weekly subcutaneous cagrilintide at doses of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, or 2.4 mg combined with semaglutide 2.4 mg, or semaglutide 2.4 mg alone, over 32 weeks. Results published in The Lancet in 2021 showed dose-dependent weight loss across all cagrilintide arms [2]. The 2.4 mg/2.4 mg combination group achieved a mean weight loss of 15.6 percent, compared with 8.0 percent in the semaglutide-alone arm (P<0.001) [2]. That is nearly double the weight loss from semaglutide monotherapy in the same trial duration.

For context: in the STEP-1 trial (N=1,961), semaglutide 2.4 mg alone produced a mean weight loss of 14.9 percent at 68 weeks versus 2.4 percent with placebo [3]. CagriSema produced 15.6 percent at only 32 weeks, suggesting the combination could substantially exceed STEP-1 results by 68 weeks. STEP-1 participants also needed 68 weeks to reach that plateau, while phase 2 CagriSema data had not yet plateaued at 32 weeks [3].

Gastrointestinal side effects in the phase 2 CagriSema study were consistent with GLP-1 receptor agonist class effects. Nausea occurred in 30 to 47 percent of participants across arms, vomiting in 10 to 30 percent, and diarrhea in 14 to 25 percent. Rates were broadly comparable to those seen with semaglutide monotherapy in STEP-1, where nausea affected 44 percent and vomiting 24 percent of participants [3]. No serious hypoglycemia events occurred in the phase 2 CagriSema cohort, consistent with the minimal hypoglycemia risk of GLP-1 agents in non-insulin-treated patients [4].

REDEFINE Phase 3 Program: Current Results

Novo Nordisk launched the REDEFINE global phase 3 program with multiple trials evaluating CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) in obesity with and without type 2 diabetes, and in cardiovascular risk populations.

REDEFINE 1 enrolled approximately 3,400 adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, without type 2 diabetes. Top-line results reported by Novo Nordisk in late 2024 showed a mean body weight reduction of approximately 22.7 percent at 68 weeks in the CagriSema arm versus approximately 7.2 percent with placebo. That 22.7 percent figure places CagriSema numerically between tirzepatide 15 mg (which produced 20.9 percent weight loss at 72 weeks in SURMOUNT-1, N=2,539) [5] and the highest-dose retatrutide cohort (28.7 percent at 68 weeks in a phase 2 trial) [6].

REDEFINE 2 focuses on adults with type 2 diabetes and obesity. STEP-2 data provide a relevant benchmark: semaglutide 2.4 mg produced 9.6 percent mean weight loss at 68 weeks in the T2D population [7]. Tirzepatide 15 mg achieved approximately 14.7 percent weight loss in SURMOUNT-2 (N=938, T2D population) at 72 weeks [8]. REDEFINE 2 results are anticipated in 2025 and will clarify whether the glycemic burden of type 2 diabetes attenuates CagriSema's weight-loss advantage, as it does for semaglutide and tirzepatide.

Novo Nordisk has not yet submitted a New Drug Application to the FDA as of early 2025. Approval, if granted, would likely require review of the full REDEFINE dataset plus a cardiovascular outcomes trial or an agreed surrogate-endpoint pathway.

How CagriSema Compares to Semaglutide Alone

Semaglutide 2.4 mg (Wegovy) is the FDA-approved reference against which CagriSema is most directly measured [9]. STEP-1 showed 14.9 percent mean weight loss at 68 weeks for semaglutide alone. STEP-5 extended follow-up to 104 weeks and found that participants who continued semaglutide 2.4 mg maintained a mean weight loss of 15.2 percent, while those who switched to placebo regained most of the lost weight [10]. This underscores that semaglutide requires continuous use for sustained effect.

CagriSema's projected 22.7 percent at 68 weeks represents roughly an 8-percentage-point improvement over semaglutide monotherapy. In a 100 kg individual, that translates to a difference of approximately 8 kg of additional body mass lost. Whether that incremental loss reduces cardiovascular events more than semaglutide alone remains unknown. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent (HR 0.80 to 95% CI 0.72 to 0.90) in adults with overweight or obesity and established cardiovascular disease but no diabetes [11]. A comparable cardiovascular outcomes trial for CagriSema has not yet reported.

The STEP-3 trial (N=611) showed that combining semaglutide 2.4 mg with intensive behavioral therapy produced a mean 16.0 percent weight loss at 68 weeks, only marginally better than semaglutide alone in STEP-1 [12]. CagriSema's phase 3 result exceeds that by over 6 percentage points without requiring intensive behavioral programs, suggesting the pharmacological addition of cagrilintide carries more weight-loss signal than behavioral intensification added to semaglutide alone.

How CagriSema Compares to Tirzepatide

Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (N=2,539) showed mean weight loss of 20.9 percent at 72 weeks with tirzepatide 15 mg, with 37.0 percent of participants achieving 25 percent or greater weight loss [5]. The Zepbound FDA label confirms the approved dose range is 2.5 mg to 15 mg weekly, titrated over 20 weeks [13].

SURMOUNT-3 demonstrated that using tirzepatide after a 12-week intensive lifestyle intervention produced a mean 18.4 percent additional weight loss from the lifestyle-run-in baseline [14]. SURMOUNT-4 showed that continued tirzepatide after 36 weeks produced 5.5 percent additional weight loss, while switching to placebo led to 14 percent weight regain over the following 52 weeks [15]. These data confirm the same durability requirement observed with semaglutide.

CagriSema's 22.7 percent versus tirzepatide 15 mg's 20.9 percent is a roughly 1.8-percentage-point difference that may not be clinically distinguishable in individual patients and has not been tested in a head-to-head trial. Direct randomized comparisons between CagriSema and tirzepatide do not exist as of early 2025. The mechanism differs materially: tirzepatide adds GIP receptor signaling on top of GLP-1 agonism, while CagriSema adds amylin-pathway satiety on top of GLP-1 agonism. Patients who respond poorly to one mechanism might respond better to the other, a hypothesis that requires prospective testing.

STEP-8 (N=338) provides the only published head-to-head data in the broader GLP-1 class: semaglutide 2.4 mg produced 15.8 percent mean weight loss at 68 weeks versus 6.4 percent for liraglutide 3.0 mg (P<0.001) [16]. Liraglutide (Saxenda) requires daily dosing and carries lower absolute efficacy, placing it a tier below both tirzepatide and CagriSema in the weight-loss hierarchy.

How CagriSema Compares to Retatrutide

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in phase 3 development. Phase 2 data (N=338, published in NEJM 2023) showed mean weight loss of 24.2 percent at 48 weeks for the 12 mg dose and 28.7 percent at 68 weeks in the dose-extension cohort [6]. Those figures are numerically higher than CagriSema's 22.7 percent at 68 weeks.

Retatrutide also does not yet have FDA approval. Both agents are in late-stage development, and both will need to demonstrate cardiovascular safety in adequately powered outcomes trials before wide clinical adoption. The glucagon receptor component of retatrutide adds metabolic benefits for hepatic fat, with phase 2 data showing meaningful reductions in liver fat fraction, an outcome not yet reported for CagriSema [6].

Choosing between CagriSema and retatrutide will not be possible from current data alone. Tolerability, titration schedules, cost, and eventual cardiovascular trial results will determine clinical positioning. What the pipeline collectively shows is that 20 to 28 percent weight loss with once-weekly injections may become achievable across multiple agents by 2026 to 2027.

Amylin Biology: Why This Mechanism Adds to GLP-1

Amylin is co-secreted with insulin in a roughly 1:100 molar ratio. Its receptors are concentrated in the area postrema (a circumventricular organ outside the blood-brain barrier), the nucleus tractus solitarius, and the arcuate nucleus. Activation of these receptors reduces meal size, prolongs gastric emptying time, and suppresses post-prandial glucagon secretion. These actions are complementary to, but do not overlap with, GLP-1 receptor actions in the same regions [17].

Pramlintide, the short-acting amylin analog approved since 2005 (FDA label for both type 1 and type 2 diabetes), produces only 2 to 3 kg weight loss when used as an adjunct to insulin therapy, largely because its pharmacokinetics require injection immediately before each meal and patient adherence is poor [18]. Cagrilintide's week-long half-life overcomes that limitation entirely, and its combination with an agent that works through a separate receptor complex produces additive reductions in energy intake that neither drug achieves alone.

The HealthRX clinical positioning framework for obesity pharmacotherapy places agents in four tiers by mean percentage body weight loss in phase 3 trials among patients without type 2 diabetes: Tier 1 (below 10 percent): liraglutide 3.0 mg, naltrexone-bupropion, orlistat. Tier 2 (10 to 15 percent): semaglutide 2.4 mg (STEP-1: 14.9 percent at 68 weeks). Tier 3 (15 to 22 percent): tirzepatide 15 mg (SURMOUNT-1: 20.9 percent at 72 weeks). Tier 4 (above 22 percent): CagriSema (REDEFINE 1: approximately 22.7 percent at 68 weeks), retatrutide 12 mg (phase 2: approximately 24 to 28.7 percent at 48 to 68 weeks). Tier 4 agents are not yet FDA-approved.

Safety Profile and Tolerability

The adverse event profile of cagrilintide in the phase 2 CagriSema study was dominated by GI effects attributable to the semaglutide component, the cagrilintide component, or both acting on overlapping brainstem satiety circuits [2]. The FDA's Wegovy label lists nausea (44 percent), diarrhea (30 percent), vomiting (24 percent), and constipation (24 percent) as the most common adverse effects for semaglutide 2.4 mg monotherapy [9]. Phase 2 CagriSema data did not show a substantially greater frequency of these events compared with semaglutide alone [2].

Calcitonin receptor activity, which amylin analogs share, raised initial theoretical concerns about medullary thyroid carcinoma (MTC) risk, the same concern flagged for GLP-1 receptor agonists. Preclinical carcinogenicity studies for cagrilintide have not revealed MTC signals in rodent models, according to Novo Nordisk's phase 3 trial registration documents. Full human safety data from REDEFINE will be needed to characterize this risk adequately.

Hypoglycemia risk with CagriSema is expected to remain low in the absence of concurrent sulfonylurea or insulin use, consistent with GLP-1 receptor agonist class behavior. AACE/ACE obesity guidelines recommend selecting agents with low hypoglycemia risk for patients without insulin-requiring diabetes [19].

Nausea management follows the same clinical approach used for semaglutide: slow dose titration, eating smaller meals, avoiding high-fat foods during escalation, and temporarily reducing dose if nausea interferes with daily function. The once-weekly fixed-dose formulation of CagriSema means clinicians will need to titrate both components simultaneously, which Novo Nordisk has addressed by designing a step-up schedule paralleling the Wegovy titration protocol.

Who Might Benefit From CagriSema

Pending FDA approval, CagriSema would logically be considered for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, who have not achieved adequate weight loss with semaglutide 2.4 mg monotherapy or tirzepatide 15 mg. The AACE/ACE 2016 clinical practice guidelines define treatment success as 5 to 10 percent weight loss with maintenance, though the guidelines predate the current high-efficacy GLP-1 generation and do not yet reflect 20-plus percent weight loss thresholds [19].

Patients who lost less than 10 percent of body weight on semaglutide after 16 weeks of maintenance dosing may be non-responders to GLP-1 stimulation alone and could theoretically derive more benefit from the addition of amylin-pathway satiety signals. This hypothesis has not been tested in a dedicated non-responder sub-study. Patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 should avoid all calcitonin-receptor-active agents until more safety data are available, the same contraindication that applies to semaglutide and liraglutide [9].

AACE and Clinical Guideline Context

The 2016 AACE/ACE obesity clinical practice guidelines, the most cited specialist guidelines in the field, recommend anti-obesity pharmacotherapy as an adjunct to lifestyle modification for all eligible patients, with preference for agents that also address comorbidities [19]. As the guideline states: "Anti-obesity medications should be used only as part of a comprehensive program that includes lifestyle management." CagriSema, if approved, would need to be positioned within that same framework.

The Obesity Society and the American Heart Association have both emphasized cardiovascular outcomes as a key metric for new obesity drugs, particularly after SELECT demonstrated that weight loss with semaglutide reduced MACE in high-risk patients by 20 percent (HR 0.80) independent of glycemic effects [11]. CagriSema will face the same scrutiny. A dedicated REDEFINE cardiovascular outcomes trial has been announced but had not yet reported by early 2025.